-+ 0.00%
-+ 0.00%
-+ 0.00%

Zentalis to present phase 1b azenosertib-paclitaxel data in ovarian cancer at ASCO

PUBT·04/21/2026 14:27:24
Listen to the news
Zentalis to present phase 1b azenosertib-paclitaxel data in ovarian cancer at ASCO
  • Zentalis Pharmaceuticals disclosed ASCO 2026 abstract acceptance for Phase 1b MUIR Part 1 study of investigational WEE1 inhibitor azenosertib with paclitaxel in platinum-resistant ovarian cancer.
  • Results have not yet been presented; data will be shown June 1, 2026 at ASCO Annual Meeting in Chicago.
  • Company expects presentation to highlight combination feasibility with early signs of anti-tumor activity in an all-comer setting, supporting broader development potential across ovarian cancer and other tumors.
  • Zentalis reiterated strategy to prioritize registration-intended monotherapy trials in Cyclin E1-positive platinum-resistant ovarian cancer through DENALI, ASPENOVA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211027PRIMZONEFULLFEED9694019) on April 21, 2026, and is solely responsible for the information contained therein.